trending Market Intelligence /marketintelligence/en/news-insights/trending/iZNItpLJ5uzKCq53U7VyFQ2 content esgSubNav
In This List

Gilead names Genentech executive as next chief medical officer

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Gilead names Genentech executive as next chief medical officer

Gilead Sciences Inc. has named former Genentech Inc. executive Merdad Parsey as the next chief medical officer, effective Nov. 1.

Parsey will oversee Gilead's global clinical development and medical affairs organizations.

Previously, Parsey was senior vice president for early clinical development for Genentech's research and early development group. Genentech is a unit of Roche Holding AG. Parsey has also held roles at Regeneron Pharmaceuticals Inc. and Merck & Co. Inc.